Summary
GlobalData's Medical Devices sector report, “Dry Powder Inhaler Devices - Medical Devices Pipeline Assessment, 2016" provides an overview of Dry Powder Inhaler Devices currently in pipeline stage.
The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Dry Powder Inhaler Devices pipeline products.
This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
- Extensive coverage of the Dry Powder Inhaler Devices under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Dry Powder Inhaler Devices and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
Reasons to buy
The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Dry Powder Inhaler Devices under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date
Companies Mentioned
Acorda Therapeutics, Inc.
Adamis Pharmaceuticals Corporation
Advent Pharmaceuticals Pty Ltd
Aespira Ltd.
AKELA Pharma Inc.
Bayer HealthCare AG
Bespak Europe Ltd.
GlaxoSmithKline Plc
Hovione FarmaCiencia SA
MannKind Corporation
Nanotherapeutics, Inc.
Nektar Therapeutics
Novartis AG
OPKO Health, Inc.
Pharmaxis Limited
Respira Therapeutics, Inc.
Sandoz International GmbH
Sheffield Hallam University
Shin Nippon Biomedical Laboratories, Ltd.
Teva Pharmaceutical Industries Ltd.
University of Kansas
University of Texas Medical Branch at Galveston
'
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 6
2 Introduction 7
2.1 Dry Powder Inhaler Devices Overview 7
3 Products under Development 8
3.1 Dry Powder Inhaler Devices - Pipeline Products by Stage of Development 8
3.2 Dry Powder Inhaler Devices - Pipeline Products by Territory 9
3.3 Dry Powder Inhaler Devices - Pipeline Products by Regulatory Path 10
3.4 Dry Powder Inhaler Devices - Pipeline Products by Estimated Approval Date 11
3.5 Dry Powder Inhaler Devices - Ongoing Clinical Trials 12
4 Dry Powder Inhaler Devices - Pipeline Products under Development by Companies 13
4.1 Dry Powder Inhaler Devices Companies - Pipeline Products by Stage of Development 13
4.2 Dry Powder Inhaler Devices - Pipeline Products by Stage of Development 15
5 Dry Powder Inhaler Devices Companies and Product Overview 16
5.1 Acorda Therapeutics, Inc. Company Overview 16
5.1.1 Acorda Therapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 16
5.2 Adamis Pharmaceuticals Corporation Company Overview 19
5.2.1 Adamis Pharmaceuticals Corporation Pipeline Products & Ongoing Clinical Trials Overview 19
5.3 Advent Pharmaceuticals Pty Ltd Company Overview 22
5.3.1 Advent Pharmaceuticals Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 22
5.4 Aespira Ltd. Company Overview 23
5.4.1 Aespira Ltd. Pipeline Products & Ongoing Clinical Trials Overview 23
5.5 AKELA Pharma Inc. (Inactive) Company Overview 24
5.5.1 AKELA Pharma Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 24
5.6 Bayer HealthCare AG Company Overview 26
5.6.1 Bayer HealthCare AG Pipeline Products & Ongoing Clinical Trials Overview 26
5.7 Bespak Europe Ltd. Company Overview 28
5.7.1 Bespak Europe Ltd. Pipeline Products & Ongoing Clinical Trials Overview 28
5.8 GlaxoSmithKline Plc Company Overview 29
5.8.1 GlaxoSmithKline Plc Pipeline Products & Ongoing Clinical Trials Overview 29
5.9 Hovione FarmaCiencia SA Company Overview 31
5.9.1 Hovione FarmaCiencia SA Pipeline Products & Ongoing Clinical Trials Overview 31
5.10 MannKind Corporation Company Overview 33
5.10.1 MannKind Corporation Pipeline Products & Ongoing Clinical Trials Overview 33
5.11 Nanotherapeutics, Inc. Company Overview 35
5.11.1 Nanotherapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 35
5.12 Nektar Therapeutics Company Overview 38
5.12.1 Nektar Therapeutics Pipeline Products & Ongoing Clinical Trials Overview 38
5.13 Novartis AG Company Overview 40
5.13.1 Novartis AG Pipeline Products & Ongoing Clinical Trials Overview 40
5.14 OPKO Health, Inc. Company Overview 44
5.14.1 OPKO Health, Inc. Pipeline Products & Ongoing Clinical Trials Overview 44
5.15 Pharmaxis Limited Company Overview 46
5.15.1 Pharmaxis Limited Pipeline Products & Ongoing Clinical Trials Overview 46
5.16 Respira Therapeutics, Inc. Company Overview 48
5.16.1 Respira Therapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 48
5.17 Sandoz International GmbH Company Overview 49
5.17.1 Sandoz International GmbH Pipeline Products & Ongoing Clinical Trials Overview 49
5.18 Sheffield Hallam University Company Overview 52
5.18.1 Sheffield Hallam University Pipeline Products & Ongoing Clinical Trials Overview 52
5.19 Shin Nippon Biomedical Laboratories, Ltd. Company Overview 53
5.19.1 Shin Nippon Biomedical Laboratories, Ltd. Pipeline Products & Ongoing Clinical Trials Overview 53
5.20 Teva Pharmaceutical Industries Ltd. Company Overview 55
5.20.1 Teva Pharmaceutical Industries Ltd. Pipeline Products & Ongoing Clinical Trials Overview 55
5.21 University of Kansas Company Overview 57
5.21.1 University of Kansas Pipeline Products & Ongoing Clinical Trials Overview 57
5.22 University of Texas Medical Branch at Galveston Company Overview 58
5.22.1 University of Texas Medical Branch at Galveston Pipeline Products & Ongoing Clinical Trials Overview 58
6 Dry Powder Inhaler Devices- Recent Developments 60
6.1 Mar 30, 2016: 80 Years of Innovation and Success in Healthcare: Chiesi Reports Significant International Growth in 2015 60
6.2 Mar 07, 2016: New Health Outcomes Data Reinforce Role of Device Selection and Peak Inspiratory Flow Rate in Treatment of COPD Patients 61
6.3 Oct 20, 2015: GSK announces positive new data comparing Incruse Ellipta to tiotropium and glycopyrronium in patients with COPD 62
6.4 Jun 16, 2015: Consort Medical announces final results 63
7 Appendix 69
7.1 Methodology 69
7.2 About GlobalData 71
7.3 Contact Us 72
7.4 Disclaimer 72
1.1 List of Tables
Table 1: Dry Powder Inhaler Devices - Pipeline Products by Stage of Development 8
Table 2: Dry Powder Inhaler Devices - Pipeline Products by Territory 9
Table 3: Dry Powder Inhaler Devices - Pipeline Products by Regulatory Path 10
Table 4: Dry Powder Inhaler Devices - Pipeline Products by Estimated Approval Date 11
Table 5: Dry Powder Inhaler Devices - Ongoing Clinical Trials 12
Table 6: Dry Powder Inhaler Devices Companies - Pipeline Products by Stage of Development 13
Table 7: Dry Powder Inhaler Devices - Pipeline Products by Stage of Development 15
Table 8: Acorda Therapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 16
Table 9: CVT-301 Drug Delivery Device - Product Status 17
Table 10: CVT-301 Drug Delivery Device - Product Description 17
Table 11: CVT-427 Drug Delivery Device - Product Status 18
Table 12: CVT-427 Drug Delivery Device - Product Description 18
Table 13: Adamis Pharmaceuticals Corporation Pipeline Products & Ongoing Clinical Trials Overview 19
Table 14: 3M Taper Dry Powder Inhaler - Product Status 20
Table 15: 3M Taper Dry Powder Inhaler - Product Description 20
Table 16: APC-5000 - Dry Powder Inhaler - Product Status 21
Table 17: APC-5000 - Dry Powder Inhaler - Product Description 21
Table 18: Advent Pharmaceuticals Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 22
Table 19: g60 Dry Powder Inhaler - Product Status 22
Table 20: g60 Dry Powder Inhaler - Product Description 22
Table 21: Aespira Ltd. Pipeline Products & Ongoing Clinical Trials Overview 23
Table 22: resQhaler - Product Status 23
Table 23: resQhaler - Product Description 23
Table 24: AKELA Pharma Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 24
Table 25: Fentanyl TAIFUN Inhaler - Product Status 25
Table 26: Fentanyl TAIFUN Inhaler - Product Description 25
Table 27: Bayer HealthCare AG Pipeline Products & Ongoing Clinical Trials Overview 26
Table 28: Ciprofloxacin Dry Powder Inhaler - Product Status 27
Table 29: Ciprofloxacin Dry Powder Inhaler - Product Description 27
Table 30: Bespak Europe Ltd. Pipeline Products & Ongoing Clinical Trials Overview 28
Table 31: DEV610 - Product Status 28
Table 32: DEV610 - Product Description 28
Table 33: GlaxoSmithKline Plc Pipeline Products & Ongoing Clinical Trials Overview 29
Table 34: Gemini Multi-Dose Combination Inhaler - Product Status 30
Table 35: Gemini Multi-Dose Combination Inhaler - Product Description 30
Table 36: Hovione FarmaCiencia SA Pipeline Products & Ongoing Clinical Trials Overview 31
Table 37: XCaps - Product Status 32
Table 38: XCaps - Product Description 32
Table 39: MannKind Corporation Pipeline Products & Ongoing Clinical Trials Overview 33
Table 40: Dreamboat - Product Status 34
Table 41: Dreamboat - Product Description 34
Table 42: Nanotherapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 35
Table 43: GelVac Intranasal Powder Vaccine Delivery System - Product Status 36
Table 44: GelVac Intranasal Powder Vaccine Delivery System - Product Description 36
Table 45: NanoGENT - Product Status 37
Table 46: NanoGENT - Product Description 37
Table 47: Nektar Therapeutics Pipeline Products & Ongoing Clinical Trials Overview 38
Table 48: Nektar Dry Powder Inhaler - Amikacin - Product Status 39
Table 49: Nektar Dry Powder Inhaler - Amikacin - Product Description 39
Table 50: Novartis AG Pipeline Products & Ongoing Clinical Trials Overview 40
Table 51: Ultibro Breezhaler - Product Status 41
Table 52: Ultibro Breezhaler - Product Description 41
Table 53: Novartis AG - Ongoing Clinical Trials Overview 42
Table 54: Ultibro Breezhaler - The Effectiveness of Single Dose Ultibro Breezhaler (Indacaterol/Glycopyrronium) by Sd-DPI Versus Ipratropium/Salbutamol by Nebulizer in Improving FEV1 and Dyspnea During Stable State of COPD 43
Table 55: OPKO Health, Inc. Pipeline Products & Ongoing Clinical Trials Overview 44
Table 56: Inspiromatic - Product Status 45
Table 57: Inspiromatic - Product Description 45
Table 58: Pharmaxis Limited Pipeline Products & Ongoing Clinical Trials Overview 46
Table 59: Orbital Dry Powder Inhaler - Product Status 47
Table 60: Orbital Dry Powder Inhaler - Product Description 47
Table 61: Respira Therapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 48
Table 62: Dry Powder Inhaler - Product Status 48
Table 63: Dry Powder Inhaler - Product Description 48
Table 64: Sandoz International GmbH Pipeline Products & Ongoing Clinical Trials Overview 49
Table 65: Solis Multi-Dose Dry Powder Inhaler - Product Status 50
Table 66: Solis Multi-Dose Dry Powder Inhaler - Product Description 50
Table 67: Unit-Dose Dry Powder Inhaler - Product Status 51
Table 68: Unit-Dose Dry Powder Inhaler - Product Description 51
Table 69: Sheffield Hallam University Pipeline Products & Ongoing Clinical Trials Overview 52
Table 70: Dry Powder Inhaler - Product Status 52
Table 71: Dry Powder Inhaler - Product Description 52
Table 72: Shin Nippon Biomedical Laboratories, Ltd. Pipeline Products & Ongoing Clinical Trials Overview 53
Table 73: µco System - Product Status 54
Table 74: µco System - Product Description 54
Table 75: Teva Pharmaceutical Industries Ltd. Pipeline Products & Ongoing Clinical Trials Overview 55
Table 76: Spiromax EU / mDPI US - Product Status 56
Table 77: Spiromax EU / mDPI US - Product Description 56
Table 78: University of Kansas Pipeline Products & Ongoing Clinical Trials Overview 57
Table 79: Dry Powder Inhaler - Product Status 57
Table 80: Dry Powder Inhaler - Product Description 57
Table 81: University of Texas Medical Branch at Galveston Pipeline Products & Ongoing Clinical Trials Overview 58
Table 82: Dry Powder Drug Delivery System - Product Status 59
Table 83: Dry Powder Drug Delivery System - Product Description 59
Table 84: Glossary 70
1.2 List of Figures
Figure 1: Dry Powder Inhaler Devices - Pipeline Products by Stage of Development 8
Figure 2: Dry Powder Inhaler Devices - Pipeline Products by Territory 9
Figure 3: Dry Powder Inhaler Devices - Pipeline Products by Regulatory Path 10
Figure 4: Dry Powder Inhaler Devices - Pipeline Products by Estimated Approval Date 11
Figure 5: Dry Powder Inhaler Devices - Ongoing Clinical Trials 12
